Viropro Stock

Viropro Current Ratio

The Current Ratio of Viropro (VPRO) as of Aug 9, 2026 is 0.15. In the previous year, Current Ratio was 0.14 — a change of 8.46% (higher).

Current Ratio

0.15

YoY

8.46%

Last updated:

Current Ratio of Viropro is 2026 0.15 . Current Ratio of Viropro was 2025 0.14 . It decreases by 8.46% higher compared to the previous year.
Access this data via the Eulerpool API

Viropro Stock analysis

What does Viropro do? Viropro Inc. is a pharmaceutical company specializing in the use of technologies for the production of biopharmaceutical products. Founded in 2004, the company aims to develop innovative and effective solutions for medical niche areas. The company is based in Canada and also has locations in Europe and Asia. With over 100 employees worldwide, Viropro offers a wide range of laboratory services to develop effective and safe medications. Viropro relies on a unique business model that utilizes cell culture technologies and bioreactors. They utilize a highly specialized cell preparation technology called "VIPER" which ensures the production of recombinant proteins and antibodies of the highest quality. Partnerships with other pharmaceutical and biotechnology companies are also an important aspect of Viropro's business model. They work with many companies to develop and bring medications to the market. Viropro's business activities extend to several areas within the bioproduct sector. However, the core element is the antibodies that the company produces and markets. Viropro's products also include human antibodies against cancer, HIV, and other serious diseases. Their portfolio also includes pharmacokinetic studies, antigen and peptide design services, as well as cell preparation and culture processing services. With a wide range of services and products, the company is able to develop customized solutions for the specific needs of its customers. In the field of cell preparation, Viropro primarily offers laboratory services that include a wide range of equipment and associated technologies. The VIPER technology developed by Viropro is a core component of this business unit. The peptide and antigen design unit offers services that focus on the identification and optimization of antibodies and peptides. The latest computer-based methods are used to simulate how certain proteins can develop on the computer. These methods are particularly effective in developing antibody-based medications. Finally, Viropro also offers pharmacokinetic services to ensure the safety and effectiveness of medications, as well as proper administration and dosage. Although the company is still relatively young, Viropro already has an impressive track record in the development and marketing of bioproducts. The company has brought several antibodies to the market and is contributing to providing lifesaving therapies for some of the most serious health problems of our time. Overall, Viropro is an exciting biotechnology company operating in a rapidly growing market and tackling some of the most important therapeutic challenges of our time. With the combination of innovative technologies and a flexible business model, the company is well-positioned to continue playing a leading role in the pharmaceutical and biotechnology industry. Viropro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viropro stock

Current Ratio of Viropro is 0.15 in 2026.

Current Ratio of Viropro changed from 0.14 to 0.15, representing a 8.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Viropro since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Viropro with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Viropro

All Key Metrics — Viropro